27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Effective, scalable dementia prevention interventions are needed to address modifiable risk factors given global burden of dementia and challenges in developing disease-modifying treatments. 1 key finding →
Design: randomized controlled trial Participants: 6,104 Evidence: high
Full summary, score breakdown and related studies → Original source
Sixteen trials, including 11,402 participants (mean age 73.2 [±5.5] years; 62.3 % female) were examined. 5 key findings →
Participants: 11,402 Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD) is a pathology with increasing prevalence in the context of a more long-lived society and it is the first cause of dementia in western countries. 2 key findings →
Design: systematic review Participants: 12,458 Evidence: high
Full summary, score breakdown and related studies → Original source
Of 300 randomized participants, 277 participants (mean age, 72.9 years; 69.3% female) were included in the modified intention-to-treat analysis (142 in the MLI group and 135 in the control group). 5 key findings →
Design: randomized controlled trial Participants: 277 Evidence: high
Full summary, score breakdown and related studies → Original source
Among cognitively unimpaired participants with a family history of dementia, changes in cognition and brain MRI outcomes from baseline to year 3 did not differ significantly between those who followed the MIND diet and those who followed the control diet with mild caloric restriction. 5 key findings →
Design: RCT Participants: 604 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. 4 key findings →
Design: randomized controlled trial Participants: 631 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A 2-year multi-domain lifestyle intervention among older adults was effective in preventing cerebrovascular events and also total CVD events among those who had history of CVD. 2 key findings →
Participants: 631 Evidence: high
Full summary, score breakdown and related studies → Original source
Among older adults with subjective cognitive concerns, mindfulness training, exercise, or both did not result in significant differences in improvement in episodic memory or executive function at 6 months. 5 key findings →
Participants: 150 Evidence: high
Full summary, score breakdown and related studies → Original source
In this clinical trial, older adults with MCI receiving aerobic-resistance exercises with sequential computerized cognitive training significantly improved cognition, although some results were inconsistent. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Dementia is a common medical condition in the ageing population, and cognitive intervention is a non-pharmacologic strategy to improve cognitive functions. 1 key finding →
Design: meta-analysis Participants: 1,489 Evidence: high
Full summary, score breakdown and related studies → Original source
We aimed to evaluate the feasibility of multidomain intervention (MI) tailored to the Korean context. 1 key finding →
Design: randomized controlled trial Participants: 51 Evidence: high
Full summary, score breakdown and related studies → Original source
The AgeWell.de intervention reduced dementia risk. 1 key finding →
Participants: 461 Evidence: low
Full summary, score breakdown and related studies → Original source
Greater adherence to a Mediterranean diet is associated with a significant improvement in health status, as seen by a significant reduction in overall mortality (9%), mortality from cardiovascular diseases (9%), incidence of or mortality from cancer (6%), and incidence of Parkinson's disease and Alzheimer's disease (13%). 3 key findings →
Design: meta-analysis Participants: 574,299 Evidence: high
Full summary, score breakdown and related studies → Original source
Significant study-site, specimen type, and batch effects were observed. 5 key findings →
Design: randomized controlled trial Participants: 604 Evidence: high
Full summary, score breakdown and related studies → Original source
Epidemiologic studies suggest that a Mediterranean diet, an antioxidant-rich cardioprotective dietary pattern, delays cognitive decline, but clinical trial evidence is lacking. 5 key findings →
Design: RCT Participants: 447 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among sedentary older adults, a 24-month moderate-intensity physical activity program compared with a health education program did not result in improvements in global or domain-specific cognitive function. 5 key findings →
Participants: 818 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Primary outcome was feasibility of the multimodal intervention, evaluated by recruitment rate during a 6-month recruitment phase, overall adherence in each intervention arm, and 6-month retention rate. 5 key findings →
Design: randomized controlled trial Participants: 93 Evidence: high
Full summary, score breakdown and related studies → Original source
Exercise interventions were performed 3.4 ± 1.4 days per week at moderate intensity (3.7 ± 0.6 metabolic equivalents) for 45.2 ± 17.0 minutes per session for 18.6 ± 10.0 weeks and consisted primarily of aerobic exercise (65%). 5 key findings →
Design: meta-analysis Participants: 1,145 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 5971 titles were reviewed and 60 studies were included in the analysis, 36 RCTs and 24 observational studies. 5 key findings →
Design: systematic review Participants: 5,971 Evidence: high
Full summary, score breakdown and related studies → Original source
Pooling data on more than 600,000 people, this meta-analysis found that people who reported feeling lonely had about a 30% higher risk of developing dementia overall, and even higher risk for vascular dementia specifically, even after accounting for depression and objective social isolation. 4 key findings →
Design: meta-analysis Participants: 608,561 Evidence: high
Full summary, score breakdown and related studies → Original source
Further studies are warranted to develop and refine the specific MIND diet for different populations. 4 key findings →
Design: meta-analysis Participants: 224,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Only RCTs were included in this study; there were eleven studies ( n = 2609 participants) of the Mediterranean diet, seven studies ( n = 313) of the ketogenic diet and one study ( n = 37) of the MIND diet. 4 key findings →
Design: systematic review Participants: 2,609 Evidence: high
Full summary, score breakdown and related studies → Original source
This systematic review suggests that CCT interventions could improve global cognitive function in patients with MCI. 5 key findings →
Design: systematic review Participants: 1,059 Evidence: high
Full summary, score breakdown and related studies → Original source
Current pharmacologic therapies are for symptomatic AD patients, whereas nonpharmacologic training is administrable before symptom onset. 1 key finding →
Design: randomized controlled trial Participants: 125 Evidence: high
Full summary, score breakdown and related studies → Original source
Providing multidomain lifestyle training through a web-platform is feasible and well-accepted, but the training should be challenging enough and adequately progress according to participants' capabilities to increase adherence. 2 key findings →
Design: randomized controlled trial Participants: 54 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →